News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Major New Review Supports the Broader Potential of CeNeS Pharmaceuticals PLC (CEN.L) COMT Inhibitor Discovery Programme


7/3/2007 1:46:30 PM

CeNeS Pharmaceuticals (AIM:CEN) (“CeNeS” or “the Company”) the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs1 further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts in the brain would be a useful agent to address profound cognitive deficits in schizophrenia and bipolar disorder. CeNeS has an ongoing discovery programme to develop novel COMT inhibitors.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES